SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2944From the technical viewpoint I can see the stock looks ready to move if only in MJ-10/12/2007
2943same here but i'm in now as i've read two reports that indicate mlnm maybob zagorin-10/12/2007
2942Was in MLNM several years ago and just didn't feel comfortable with the stocMJ-10/12/2007
2941Millennium Upgraded to 'Outperform,' Baird Analyst Says Cancer Drug SaleIcebrg-10/12/2007
2940A penny is a penny!tom pope-10/10/2007
2939<i>Piper Jaffray & Co. resumes coverage of Millennium Pharmaceuticals Steve Lokness-10/10/2007
2938PHARMA MARKET:Millennium Looks To Expand Velcade Label,Sales Dow Jones October 0Icebrg-10/10/2007
2937J&J To Launch Money-Back Guarantee For Cancer Drug In UK Oct 10, 2007 12:5LJM-10/10/2007
2936Piper Jaffray & Co. Resumes Coverage of Millennium Pharmaceuticals (MLNM) atIcebrg-10/10/2007
2935Millenium Pharmaceuticals By Roopak Chakravarty Oct 02, 2007 Millenium Pharmaceubob zagorin-10/9/2007
2934[Bortezomib as induction therapy prior to stem cell transplantation in frontlinetuck-10/9/2007
2933[Stimulation of new bone formation by the proteasome inhibitor, bortezomib: impltuck-10/4/2007
2932The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-mIcebrg-10/4/2007
2931Life Sciences Leader Joins Millennium Board of Directors Thursday October 4, 7:0Icebrg-10/4/2007
2930Phase I trial of the proteasome inhibitor bortezomib in combination with carboplIcebrg-10/3/2007
2929Inhibition of the Canonical IKK/NFkappaB Pathway Sensitizes Human Cancer Cells tIcebrg-9/26/2007
2928omicsomics.blogspot.comIcebrg-9/25/2007
2927Business gets into biking Some call phenomenon ‘the new golf’ By Herald staff SuIcebrg-9/24/2007
2926Bortezomib Sensitizes Non Hodgkin's Lymphoma Cells to Apoptosis Induced by AIcebrg-9/19/2007
2925Millennium: Positive Velcade Phase III Results In New MM therapeuticsdaily.com.Icebrg-9/19/2007
2924Birchenough's view: VISTA Positive, Impact Uncertain [Posted by microcapfunIcebrg-9/19/2007
2923Ursolic Acid Inhibits STAT3 Activation Pathway Leading to Suppression of ProlifeIcebrg-9/18/2007
2922Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due tIcebrg-9/18/2007
2921Let's hope they spend a little more frugally then they did at mlnm. $2.535rkrw-9/14/2007
2920Biotech Battle Scars Matthew Herper, 09.14.07, 10:09 AM ET A group of executivIcebrg-9/14/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News